|
|
Evotec Se
EVO's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Evotec Se growth rates, revenue grew
by 3.99 % in the fourth quarter of 2023 from the same quarter a year ago.
Ranking at No. 649
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Evotec Se net loss decreased from $-197 millions, to $-94 millions in fourth quarter of 2023,
• More on EVO's Growth
|
|
Evotec Se
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.62 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 0.86.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
• More on EVO's Valuation
|
|
|
|
|
Evotec Se
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.62 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 0.86.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
Evotec Se Price to Book Ratio is at 0.6 lower than Industry Avg. of 34.77. and higher than S&P 500 Avg. of 0.01
• More on EVO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
